PAPERS DISCUSSED BY DR GEORGE (RENAL CELL AND PROSTATE CANCER)

Figlin RA et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Proc ASCO 2008;Abstract 5024.

Escudier BJ et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. Proc ASCO 2008;Abstract 5025.

Whorf RC et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). Proc ASCO 2008;Abstract 5010.

Feldman DR et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. Proc ASCO 2008;Abstract 5100.

Sosman JA et al. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). Proc ASCO 2008;Abstract 5011.

Sridhar SS et al. Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium. Proc ASCO 2008;Abstract 5047.

Bajetta E et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) >65 years with metastatic renal cell carcinoma (mRCC). Proc ASCO 2008;Abstract 5095.

Hariharan S et al. Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (mets): Data from an expanded access trial. Proc ASCO 2008;Abstract 5094.

Figg WD et al. Randomized phase III trial of thalidomide (Th) or placebo (P) for nonmetastatic PSA recurrent prostate cancer (PCa) treated with intermittent therapy. Proc ASCO 2008;Abstract 5016.

Ning YM et al. Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (Doc) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). Proc ASCO 2008;Abstract 5000.

Scher HI et al. Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC). Proc ASCO 2008;Abstract 5006.

De Bono JS et al. Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC). Proc ASCO 2008;Abstract 5005.